Schizophrenia Research
Volume 88, Issue 1 , Pages 63-72 , December 2006

A model of anticholinergic activity of atypical antipsychotic medications

  • Marci L. Chew

      Affiliations

    • Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA
    • Geriatric Psychopharmacology Laboratory, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • ,
  • Benoit H. Mulsant

      Affiliations

    • Geriatric Psychopharmacology Laboratory, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • Geriatric Mental Health Program, Centre for Addiction and Mental Health, 1001 Queen Street West, Toronto, Ontario, Canada M6J 1H4
    • Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    • Corresponding Author InformationCorresponding author. CAMH, #3011, 1001 Queen Street West, Toronto, Ontario, Canada M6J 1H4. Tel.: +1 416 535 8501x3656; fax: +1 416 583 1307.
    • ,
  • Bruce G. Pollock

      Affiliations

    • Geriatric Psychopharmacology Laboratory, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • Geriatric Mental Health Program, Centre for Addiction and Mental Health, 1001 Queen Street West, Toronto, Ontario, Canada M6J 1H4
    • Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    • The Rotman Research Institute, Toronto, Canada
    • ,
  • Mark E. Lehman

      Affiliations

    • Ortho McNeil-Janssen Scientific Affairs, LLC, 135 Calumet Court, Crestview Hills, KY 41017, USA
    • ,
  • Andrew Greenspan

      Affiliations

    • Johnson&Johnson Pharmaceutical Research and Development, 1125 Trenton-Harbourton Road, Titusville, NJ 08530, USA
    • ,
  • Margaret A. Kirshner

      Affiliations

    • Geriatric Psychopharmacology Laboratory, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • ,
  • Robert R. Bies

      Affiliations

    • Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA
    • Geriatric Psychopharmacology Laboratory, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    • ,
  • Shitij Kapur

      Affiliations

    • Geriatric Mental Health Program, Centre for Addiction and Mental Health, 1001 Queen Street West, Toronto, Ontario, Canada M6J 1H4
    • Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    • ,
  • Georges Gharabawi

      Affiliations

    • Medical Affairs, Janssen Pharmaceutica, Inc, 1125 Trenton-Harbourton Road, Titusville, NJ 08530, USA

Received 24 March 2006 ,Revised 5 July 2006 ,Accepted 6 July 2006.

References 

  1. Aaltonen L, Syvalahti E, Iisalo E, Peltomaki T. Anticholinergic activity in the serum of patients receiving maintenance amitriptyline or doxepin therapy. Acta Pharmacol. Toxicol. 1985;56:75–80
  2. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. J. Clin. Psychiatry. 2004;65(Suppl 2):5–104
  3. Aripiprazole, package insert, 2005. Bristol-Meyers Squibb Company and Otsuka America Pharmaceutical, Inc. (Revised April 2005).
  4. Barak Y, Wittenberg N, Naor S, Kutzuk D, Weizman A. Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy. Compr. Psychiatry. 1999;40:320–325
  5. Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 1992;260:576–580
  6. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science. 1987;237:527–532
  7. Bymaster FP, Falcone JF. Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium. Eur. J. Pharmacol. 2000;390:245–248
  8. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87–96
  9. Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, McKinzie DL. Muscarinic mechanisms of antipsychotic atypicality. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2003;27:1125–1143
  10. Bymaster FP, McKinzie DL, Felder CC, Wess J. Use of M1–M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem. Res. 2003;28:437–442
  11. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 1999;37:177–193
  12. Caulfield MP. Murscarinic receptors—characterization, coupling and function. Pharmacol. Ther. 1993;58:319–379
  13. Chengappa KN, Pollock BG, Parepally H, Levine J, Kirshner MA, Brar JS, et al. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J. Clin. Psychopharmacol. 2000;20:311–316
  14. Chew ML, Mulsant BH, Pollock BG. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am. J. Geriatr. Psychiatry. 2005;13:535–538
  15. Clozapine, package insert, 2005. Novartis Pharmaceuticals Cooperation (revised May 2005).
  16. de Leon J, Odom-White A, Josiassen RC, Diaz FJ, Cooper TB, Simpson GM. Serum antimuscarinic activity during clozapine treatment. J. Clin. Psychopharmacol. 2003;23:336–341
  17. Felder CC, Porter AC, Skillman TL, Zhang L, Bymaster FP, Nathanson NM, et al. Elucidating the role of muscarinic receptors in psychosis. Life Sci. 2001;68:2605–2613
  18. Flacker JM, Lipsitz LA. Serum anticholinergic activity changes with acute illness in elderly medical patients. J. Gerontol., Ser. A, Biol. Sci. Med. Sci. 1999;54:M12–M16
  19. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J. Neurochem. 1995;64:1888–1891
  20. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172:1703–1709
  21. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther. Drug Monit. 2003;25:46–53
  22. Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, et al. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 1999;96:10483–10488
  23. Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety. Expert Opin. Pharmacother. 2002;3:1773–1781
  24. Hamilton SE, Hardouin SN, Anagnostaras SG, Murphy GG, Richmond KN, Silva AJ, et al. Alteration of cardiovascular and neuronal function in M1 knockout mice. Life Sci. 2001;68:2489–2493
  25. Hitri A, Craft RB, Fallon J, Sethi R, Sinha D. Serum neuroleptic and anticholinergic activity in relationship to cognitive toxicity of antiparkinsonian agents in schizophrenic patients. Psychopharmacol. Bull. 1987;23:33–37
  26. Huang F, Lasseter KC, Janssens L, Verhaeghe T, Lau H, Zhao Q. Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. J. Clin. Pharmacol. 2002;42:1341–1351
  27. Ichikawa J, Chung YC, Li Z, Dai J, Meltzer HY. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res. 2002;958:176–184
  28. Iisalo E, Aaltonen L. Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy. Br. J. Clin. Pharmacol. 1984;17:325–329
  29. Jaskiw GE, Thyrum PT, Fuller MA, Arvanitis LA, Yeh C. Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders. Clin. Pharmacokinet. 2004;43:1025–1035
  30. Jerusalinsky D, Kornisiuk E, Alfaro P, Quillfeldt J, Alonso M, Verde ER, et al. Muscarinic toxin selective for m4 receptors impairs memory in the rat. NeuroReport. 1998;9:1407–1411
  31. Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DG, Bourne RC, et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol. Med. 1983;13:513–527
  32. Katz IR, Greenberg WM, Barr GA, Garbarino C, Buckley P, Smith D. Screening for cognitive toxicity of anticholinergic drugs. J. Clin. Psychiatry. 1985;46:323–326
  33. Lachowicz JE, Duffy RA, Ruperto V, Kozlowski J, Zhou G, Clader J, et al. Facilitation of acetylcholine release and improvement in cognition by a selective M2 muscarinic antagonist, SCH 72788. Life Sci. 2001;68:2585–2592
  34. Lavalaye J, Booij J, Linszen DH, Reneman L, van Royen EA. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A [123I]-IDEX SPECT study. Psychopharmacology (Berl.). 2001;156:53–57
  35. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005;353:1209–1223
  36. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J. Clin. Pharmacol. 2004;44:179–187
  37. Matsui M, Yamada S, Oki T, Manabe T, Taketo MM, Ehlert FJ. Functional analysis of muscarinic acetylcholine receptors using knockout mice. Life Sci. 2004;75:2971–2981
  38. Mauri MC, Laini V, Boscati L, Rudelli R, Salvi V, Orlandi R, et al. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur. Psychiatr. 2001;16:57–63
  39. Miller PS, Richardson JS, Jyu CA, Lemay JS, Hiscock M, Keegan DL. Association of low serum anticholinergic levels and cognitive impairment in elderly presurgical patients. Am. J. Psychiatry. 1988;145:342–345
  40. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry. 2004;161:116–124
  41. Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 2003;9:159–186
  42. Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch. Gen. Psychiatry. 2003;60:198–203
  43. Mulsant BH, Gharabawi GM, Bossie CA, Mao L, Martinez RA, Tune LE, et al. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J. Clin. Psychiatry. 2004;65:1708–1714
  44. Nebes RD, Pollock BG, Mulsant BH, Kirshner MA, Halligan E, Zmuda M, et al. Low-level serum anticholinergicity as a source of baseline cognitive heterogeneity in geriatric depressed patients. Psychopharmacol. Bull. 1997;33:715–720
  45. Olanzapine, package insert, 2005. Eli Lilly and Company (revised May 2005).
  46. Perlick D, Stastny P, Katz I, Mayer M, Mattis S. Memory deficits and anticholinergic levels in chronic schizophrenia. Am. J. Psychiatry. 1986;143:230–232
  47. Quetiapine, package insert, 2005. AstraZeneca Pharmaceuticals LP.
  48. Raedler TJ, Knable MB, Jones DW, Lafargue T, Urbina RA, Egan MF, et al. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology. 2000;23:56–68
  49. Raedler TJ, Knable MB, Jones DW, Urbina RA, Egan MF, Weinberger DR. Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology. 2003;28:1531–1537
  50. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry. 1999;60(Suppl 10):5–14
  51. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29–39
  52. Risperidone, package insert, 2005. Janssen Pharmaceutica Products L.P. (revised May 2005).
  53. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J. Clin. Psychopharmacol. 2004;24:70–78
  54. Schmidt AW, Lebel LA, Howard HR, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. 2001;425:197–201
  55. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400–1411
  56. Strauss ME, Reynolds KS, Jayaram G, Tune LE. Effects of anticholinergic medication on memory in schizophrenia. Schizophr. Res. 1990;3:127–129
  57. Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann. Clin. Psychiatry. 2002;14:123–129
  58. Tice MA, Hashemi T, Taylor LA, McQuade RD. Distribution of muscarinic receptor subtypes in rat brain from postnatal to old age. Brain Res. Dev. Brain Res. 1996;92:70–76
  59. Tracy JI, Monaco CA, Abraham G, Josiassen RC, Pollock BG. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. J. Clin. Psychiatry. 1998;59:184–188
  60. Tracy JI, Monaco C, Giovannetti T, Abraham G, Josiassen RC. Anticholinergicity and cognitive processing in chronic schizophrenia. Biol. Psychol. 2001;56:1–22
  61. Tune L, Coyle JT. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch. Gen. Psychiatry. 1980;37:293–297
  62. Tune L, Coyle JT. Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology (Berl.). 1981;75:9–15
  63. Tune LE, Strauss ME, Lew MF, Breitlinger E, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am. J. Psychiatry. 1982;139:1460–1462
  64. Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis. Assoc. Disord. 1998;12:304–312
  65. Wilner KD, Tensfeldt TG, Baris B, Smolarek TA, Turncliff RZ, Colburn WA, et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br. J. Clin. Pharmacol. 2000;49(Suppl 1):15S–20S
  66. Wong YW, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J. Clin. Psychopharmacol. 2001;21:89–93
  67. Ziprasidone, package insert, 2005. Pfizer, Inc. (revised May 2005).

PII: S0920-9964(06)00315-X

doi: 10.1016/j.schres.2006.07.011

Schizophrenia Research
Volume 88, Issue 1 , Pages 63-72 , December 2006

Article Tools

* Image Usage & Resolution